Contact Us 888-901-2226
Donate Now
genomics consortium

Bladder Cancer Genomics Consortium

In an effort to further advance bladder cancer research, BCAN has launched the Bladder Cancer Genomics Consortium (BCGC). The BCGC’s ultimate goal is to provide the opportunity for every patient to be an exceptional responder to personalized therapy while advancing collaborative research to support the development of life-saving treatments for bladder cancer.

The first project for BCGC will be a large-scale genomically-driven bladder cancer study, in partnership with a non-profit corporation bringing cutting-edge diagnostics and biomarker driven clinical trials to cancer patients. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center. HCRN, an independent non-profit Contract Research Organization, has deep experience in supporting multi-institutional investigator-initiated clinical trials.

Eight medical centers, recognized for their expertise in bladder cancer will participate in the study. The participating institutions will initially enroll 200 patients with metastatic urothelial cancer. Patients tumors will be genomically profiled using next-generation sequencing (NGS). The patients’ physicians will receive the results of the NGS profiles and information about potential clinical trials related to their patients’ NGS findings. HCRN will house the data created in the study, which will be accessible to all partners of BCGC for collaborative translational research and to help facilitate the development of novel clinical trials.

BCAN is investing an initial $1.6 million from generous donors, including the James Family Foundation. The funds will underwrite the study management, support services, and genomic sequencing –costs that are often a barrier to personalized care for patients.

For more information, please contact us at 1-888-901-2226.

BCGC Press Release

BCGC Advisory Committee

Matthew Milowsky, M.D., University of North Carolina
BCGC Chair

Hikmat Al-Ahmadie, M.D., Memorial Sloan-Kettering Cancer Center

Dean Bajorin, M.D., Memorial Sloan-Kettering Cancer Center

Noah Hahn, M.D., Johns Hopkins University School of Medicine

David Kwiatkowski, M.D., Ph.D, Dana Farber Cancer Institute

William Kim, M.D., University of North Carolina

Seth Lerner, M.D., Baylor College of Medicine

David McConkey, Ph.D., MD Anderson Cancer Center

Jonathan Rosenberg, M.D., Memorial Sloan-Kettering Cancer Center

William Shipley, M.D., Massachusetts General Hospital

Walter Stadler, M.D., The University of Chicago

Gary Steinberg, M.D., The University of Chicago